Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1037
- Registration Number
- NCT01545791
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT01547169
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT01542450
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT01542476
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1889
- Registration Number
- NCT01542424
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 480
- Registration Number
- NCT01542489
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4464
- Registration Number
- NCT01542463
A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 350
- Registration Number
- NCT01513473
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT01498939
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Comparison of Two Insulin Detemir Formulations in Healthy Volunteers
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34
- Registration Number
- NCT01498926
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.